China Pharma Holdings (CPHI) Other Accumulated Expenses (2019 - 2026)

China Pharma Holdings has reported Other Accumulated Expenses for 8 years, with the latest figure at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 20.56% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (up 20.56% YoY), and the FY2025 full-year result was $1.9 million, up 20.91% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $1.9 million, roughly flat from $1.9 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $2.6 million in Q1 2022, with the low at $24000.0 in Q3 2024.
• Historically, Other Accumulated Expenses has averaged $1.8 million across 5 years, with a median of $1.9 million in 2025.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses plunged 97.84% — and 2025, when it surged 6614.61%.
• China Pharma Holdings' Other Accumulated Expenses stood at $2.5 million in 2022, then sank by 49.29% to $1.3 million in 2023, then gained by 26.44% to $1.6 million in 2024, then increased by 20.91% to $1.9 million in 2025, then grew by 0.21% to $1.9 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.9 million (Q1 2026), $1.9 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.